EE52 Cost-Minimisation Analysis of Ravulizumab Compared With Eculizumab in Patients With Atypical Hemolytic Uremic Syndrome (AHUS) in the Netherlands
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.305
https://www.valueinhealthjournal.com/article/S1098-3015(22)02509-8/fulltext
Section Title :
Section Order :
12113
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02509-8&doi=10.1016/j.jval.2022.09.305